Compliance distress briefs — top 8 in-ICP firms
Each brief is built only from real FDA data. The outreach email maps the firm's actual recall reason to the specific Atlas module that addresses it. Emails are composed examples to spec — none are sent, no contact names are invented.
SUN PHARMACEUTICAL INDUSTRIES INC
US pharma (CQO segment) · Princeton NJ United States
100/100
Worst classificationClass I
Distinct FDA events (15mo)13
Most recent2026-07-01 (7d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +20Quality-system +10Ongoing +5
FDA reason on file (verbatim)Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfetamine dimesylate capsules.
Quality-system terms matchedassay, contamination, degradation, dissolution, impurit, oos
Target roleChief Quality Officer / VP of Quality · Atlas module483/EIR search + peer benchmarking
Drafted outreach email (composed to spec — not sent)
Subject: SUN PHARMACEUTICAL INDUSTRIES INC: Class I recall (2026-07-01) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at SUN PHARMACEUTICAL INDUSTRIES INC.
I track FDA enforcement filings. On 2026-07-01, SUN PHARMACEUTICAL INDUSTRIES INC filed a Class I recall; the FDA reason on file reads: "Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25C, 60%RH) for Lisdexamfet". This isn't isolated — FDA records 13 distinct enforcement events for SUN PHARMACEUTICAL INDUSTRIES INC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. 483/EIR search + peer benchmarking: Pull every 483 citing the same stability/OOS failure mode across peer manufacturers and see the corrective actions FDA accepted.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
Amneal Pharmaceuticals, LLC
US pharma (CQO segment) · Bridgewater NJ United States
94/100
Worst classificationClass I
Distinct FDA events (15mo)6
Most recent2026-06-17 (21d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +14Quality-system +10Ongoing +5
FDA reason on file (verbatim)Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25C/60%RH).
Quality-system terms matchedcontamination, cross-contamination, degradation, impurit, microbial, nitroso
Target roleChief Quality Officer / VP of Quality · Atlas modulePeer benchmarking + CFR trend analysis
Drafted outreach email (composed to spec — not sent)
Subject: Amneal Pharmaceuticals, LLC: Class I recall (2026-06-17) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at Amneal Pharmaceuticals, LLC.
I track FDA enforcement filings. On 2026-06-17, Amneal Pharmaceuticals, LLC filed a Class I recall; the FDA reason on file reads: "Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stabi". This isn't isolated — FDA records 6 distinct enforcement events for Amneal Pharmaceuticals, LLC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. Peer benchmarking + CFR trend analysis: See every other firm cited for the same nitrosamine/impurity class of observation, which investigators are driving it, and how they closed it out — before your next inspection.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
CareFusion 213, LLC
US pharma (CQO segment) · El Paso TX United States
94/100
Worst classificationClass I
Distinct FDA events (15mo)5
Most recent2026-07-08 (0d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +14Quality-system +10Ongoing +5
FDA reason on file (verbatim)Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Quality-system terms matchedcontamination, sterility
Target roleChief Quality Officer / VP of Quality · Atlas moduleScout gap-assessment + investigator profiles
Drafted outreach email (composed to spec — not sent)
Subject: CareFusion 213, LLC: Class I recall (2026-07-08) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at CareFusion 213, LLC.
I track FDA enforcement filings. On 2026-07-08, CareFusion 213, LLC filed a Class I recall; the FDA reason on file reads: "Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of th". This isn't isolated — FDA records 5 distinct enforcement events for CareFusion 213, LLC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. Scout gap-assessment + investigator profiles: Run your sterility/contamination SOPs against the real 483 observations in the same category, and pull the profile of the investigator most likely to cover your site.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
Sandoz Inc
US pharma (CQO segment) · Princeton NJ United States
94/100
Worst classificationClass I
Distinct FDA events (15mo)4
Most recent2026-06-24 (14d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +14Quality-system +10Ongoing +5
FDA reason on file (verbatim)Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 million Unit. The vials contained Cefozalin
Quality-system terms matchedcgmp
Target roleChief Quality Officer / VP of Quality · Atlas moduleAI Copilot + Warning Letter corpus
Drafted outreach email (composed to spec — not sent)
Subject: Sandoz Inc: Class I recall (2026-06-24) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at Sandoz Inc.
I track FDA enforcement filings. On 2026-06-24, Sandoz Inc filed a Class I recall; the FDA reason on file reads: "Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 million Unit". This isn't isolated — FDA records 4 distinct enforcement events for Sandoz Inc in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. AI Copilot + Warning Letter corpus: A Class I event draws follow-up scrutiny — see how peers who took Class I recalls fared at their next inspection, and what the recurring 483 themes were.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
Haleon US Holdings LLC
US pharma (CQO segment) · Warren NJ United States
94/100
Worst classificationClass I
Distinct FDA events (15mo)4
Most recent2026-06-17 (21d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +14Quality-system +10Ongoing +5
FDA reason on file (verbatim)Labeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton
Quality-system terms matchedcontamination
Target roleChief Quality Officer / VP of Quality · Atlas moduleAI Copilot + Warning Letter corpus
Drafted outreach email (composed to spec — not sent)
Subject: Haleon US Holdings LLC: Class I recall (2026-06-17) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at Haleon US Holdings LLC.
I track FDA enforcement filings. On 2026-06-17, Haleon US Holdings LLC filed a Class I recall; the FDA reason on file reads: "Labeling: Label Mix-up: The outer carton is labelled Fresh Mint". This isn't isolated — FDA records 4 distinct enforcement events for Haleon US Holdings LLC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. AI Copilot + Warning Letter corpus: A Class I event draws follow-up scrutiny — see how peers who took Class I recalls fared at their next inspection, and what the recurring 483 themes were.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
IntegraDose Compounding Services LLC
US pharma (CQO segment) · Shoreview MN United States
88/100
Worst classificationClass I
Distinct FDA events (15mo)3
Most recent2026-06-24 (14d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +8Quality-system +10Ongoing +5
FDA reason on file (verbatim)Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.
Quality-system terms matchedsubpotent
Target roleChief Quality Officer / VP of Quality · Atlas moduleAI Copilot + Warning Letter corpus
Drafted outreach email (composed to spec — not sent)
Subject: IntegraDose Compounding Services LLC: Class I recall (2026-06-24) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at IntegraDose Compounding Services LLC.
I track FDA enforcement filings. On 2026-06-24, IntegraDose Compounding Services LLC filed a Class I recall; the FDA reason on file reads: "Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.". This isn't isolated — FDA records 3 distinct enforcement events for IntegraDose Compounding Services LLC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. AI Copilot + Warning Letter corpus: A Class I event draws follow-up scrutiny — see how peers who took Class I recalls fared at their next inspection, and what the recurring 483 themes were.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
Fresenius Kabi USA, LLC
US pharma (CQO segment) · Lake Zurich IL United States
88/100
Worst classificationClass I
Distinct FDA events (15mo)3
Most recent2026-06-17 (21d before anchor)
StatusOngoing
Severity +40Recency +25Systemic +8Quality-system +10Ongoing +5
FDA reason on file (verbatim)Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Quality-system terms matchedcontamination, degradation, endotoxin, impurit, microbial, sterile
Target roleChief Quality Officer / VP of Quality · Atlas moduleScout gap-assessment + investigator profiles
Drafted outreach email (composed to spec — not sent)
Subject: Fresenius Kabi USA, LLC: Class I recall (2026-06-17) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at Fresenius Kabi USA, LLC.
I track FDA enforcement filings. On 2026-06-17, Fresenius Kabi USA, LLC filed a Class I recall; the FDA reason on file reads: "Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.". This isn't isolated — FDA records 3 distinct enforcement events for Fresenius Kabi USA, LLC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. Scout gap-assessment + investigator profiles: Run your sterility/contamination SOPs against the real 483 observations in the same category, and pull the profile of the investigator most likely to cover your site.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)
B BRAUN MEDICAL INC
US pharma (CQO segment) · Allentown PA United States
87/100
Worst classificationClass I
Distinct FDA events (15mo)6
Most recent2026-05-13 (56d before anchor)
StatusOngoing
Severity +40Recency +18Systemic +14Quality-system +10Ongoing +5
FDA reason on file (verbatim)Lack of assurance of sterility: pinholes, within the finger boxes used during Form Fill Seal process resulting in leaks.
Quality-system terms matchedparticulate, sterility
Target roleChief Quality Officer / VP of Quality · Atlas moduleScout gap-assessment + investigator profiles
Drafted outreach email (composed to spec — not sent)
Subject: B BRAUN MEDICAL INC: Class I recall (2026-05-13) — how peers closed the same finding
Hi — sending this to whoever owns quality/compliance at B BRAUN MEDICAL INC.
I track FDA enforcement filings. On 2026-05-13, B BRAUN MEDICAL INC filed a Class I recall; the FDA reason on file reads: "Lack of assurance of sterility: pinholes, within the finger boxes used during Form Fill Seal process resulting in leaks.". This isn't isolated — FDA records 6 distinct enforcement events for B BRAUN MEDICAL INC in the ~15 months covered by this pull.
The reason I'm reaching out: the teams that come out of an event like this cleanest are the ones who benchmark it fast — what the same observation looked like at peer manufacturers, which CFR sections and investigators keep recurring, and what corrective actions FDA actually accepted.
That's what Atlas does. Scout gap-assessment + investigator profiles: Run your sterility/contamination SOPs against the real 483 observations in the same category, and pull the profile of the investigator most likely to cover your site.
We index 100,000+ inspection observations, 30,000+ Form 483s/EIRs and 11,800+ Warning Letters — searchable in seconds, at roughly a third of the cost of legacy tools. Cipla, Zydus, Torrent, Strides and Natco already run on it.
Worth a 20-minute look at your specific situation? I can pull the peer set for this exact finding before we even talk.
— [SDR name], Atlas Compliance
(This is a composed example for a portfolio demo. It has not been sent.)